BFM Podcast
Duopharma Seeking to Diversify Manufacturing Domain
13-Mar-24 08:00
Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech
Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
More articles on BFM Podcast
Doctor in the House: Can Malaysia Be A Regional Hub for Clinical Trials?
Created by Tan KW | Apr 26, 2024
Malaysia's First Astrophysicist Discovered Astrophysics Through Poetry
Created by Tan KW | Apr 26, 2024
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Apps
Top Articles
1
2
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
6
BFM Podcast
7
BFM Podcast
8
Good Articles to Share
Gen AI is less efficient than crypto: Early #facebook investor #shorts
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
